Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study

[1]  C. Vlachopoulos,et al.  Cost-Utility Of Ranolazine For The Symptomatic Treatment Of Patients With Chronic Angina Pectoris In Greece. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  S. Gorokhova,et al.  Cost-Effectiveness Of Ranolazine For The Treatment Of Angina Pectoris In Russia. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  G. Filippatos,et al.  Medical management of stable angina. , 2014, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[4]  C. Coleman,et al.  Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris. , 2014, The American journal of cardiology.

[5]  Á. Hidalgo-Vega,et al.  Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain , 2014, The European Journal of Health Economics.

[6]  P. Schwartz,et al.  The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[7]  J. Kaski,et al.  Pharmacological treatment of chronic stable angina pectoris. , 2013, Clinical medicine.

[8]  G. Keating.  Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. , 2013, Drugs.

[9]  E. Buysman,et al.  Costs and clinical outcomes associated with use of ranolazine for treatment of angina. , 2012, Clinical therapeutics.

[10]  A. Cohen-Solal,et al.  An unusual cause of systolic murmur. , 2011, Archives of cardiovascular diseases.

[11]  D. Brixner,et al.  Health Resource Utilization and Direct Costs Associated with Angina for Patients with Coronary Artery Disease in a US Managed Care Setting. , 2011, American health & drug benefits.

[12]  E. Braunwald,et al.  Economic Impact of Angina After an Acute Coronary Syndrome: Insights From the MERLIN-TIMI 36 Trial , 2009, Circulation. Cardiovascular quality and outcomes.

[13]  E. Braunwald,et al.  Effects of Ranolazine on Disease-Specific Health Status and Quality of Life Among Patients With Acute Coronary Syndromes: Results from the MERLIN-TIMI 36 Randomized Trial , 2008, Circulation. Cardiovascular quality and outcomes.

[14]  M. Aalabaf-Sabaghi.  Decision modelling for health economic evaluation , 2007, Journal of Epidemiology and Community Health.

[15]  A. Skene,et al.  Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. , 2007, JAMA.

[16]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[17]  P. Stone,et al.  Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. , 2006 .

[18]  G. Mancia,et al.  Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. , 2006, European heart journal.

[19]  J. Camm,et al.  [Guidelines on the management of stable angina pectoris: executive summary]. , 2006, Giornale italiano di cardiologia.

[20]  Mark Sculpher,et al.  Estimating utility data from clinical indicators for patients with stable angina , 2005, The European Journal of Health Economics.

[21]  Jean-Claude Tardif,et al.  Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. , 2005, European heart journal.

[22]  B. Chaitman,et al.  Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. , 2005, Journal of the American College of Cardiology.

[23]  B. Chaitman,et al.  Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. , 2005, The American journal of cardiology.

[24]  P. McCollam,et al.  Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting , 2005, Journal of managed care pharmacy : JMCP.

[25]  M. Hlatky,et al.  A systematic review of the economic burden of chronic angina. , 2004, The American journal of managed care.

[26]  J. Shryock,et al.  Antagonism by Ranolazine of the Pro-Arrhythmic Effects of Increasing Late INa in Guinea Pig Ventricular Myocytes , 2004, Journal of cardiovascular pharmacology.

[27]  C. Antzelevitch,et al.  Antiarrhythmic Effects of Ranolazine in a Guinea Pig in Vitro Model of Long-QT Syndrome , 2004, Journal of Pharmacology and Experimental Therapeutics.

[28]  B. Chaitman,et al.  Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. , 2004, Journal of the American College of Cardiology.

[29]  B. Chaitman,et al.  Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. , 2004, JAMA.

[30]  J. McMurray,et al.  The current cost of angina pectoris to the National Health Service in the UK , 2003, Heart.

[31]  J. Borer,et al.  Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial , 2003, Circulation.

[32]  J. Spertus,et al.  Health Status Predicts Long-Term Outcome in Outpatients With Coronary Disease , 2002, Circulation.

[33]  S. Thompson,et al.  Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. , 2000, Statistics in medicine.

[34]  R A Deyo,et al.  Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. , 1995, Journal of the American College of Cardiology.

[35]  W. Aronow.  Management of stable angina. , 1973, The New England journal of medicine.